Abstract
Biologics are effective treatments for people with rheumatoid arthritis (RA) but are associated with adverse effects and are costly. Tapering of biologics is recommended when people with RA achieve remission but is not without risk of disease flare-up. Little is currently known about how the preferences of people with RA would influence their decisions to accept biologics tapering. This study aimed to assess the preference of people with RA for biologics tapering.